Haematologica / The Hematology Journal
Herausgeber
Ferrata Storti Foundation
International Standard Serial Number (ISSN )
0390-6078
Electronic International Standard Serial Number ( EISSN )
1592-8721
ISSN gedruckt
0390-6078
http://www.bibliothek.uni-regensburg.de/ezeit/?2030158-
2025
Cyclin C promotes development and progression of B-cell acute lymphoblastic leukemia by counteracting p53-mediated stress responses
2023 Oncogenic TYK2P760L kinase is effectively targeted by combinatorial TYK2, mTOR and CDK4/6 kinase blockade.
2021 Inducible deletion of CDK4 and CDK6-deciphering CDK4/6 inhibitor effects in the hematopoietic system
2021 Whole exome sequencing reveals NOTCH1 mutations in anaplastic large cell lymphoma and points to Notch both as a key pathway and a potential therapeutic target
2020 High activation of STAT5A drives peripheral T-cell lymphoma and leukemia
2019 The stromal microenvironment provides an escape route from FLT3 inhibitors through the GAS6-AXL-STAT5 axis.
2018 Normal and pathological erythropoiesis in adults: from gene regulation to targeted treatment concepts
2018 The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis
2017 Cdk6 contributes to cytoskeletal stability in erythroid cells
2017 Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemia.
2017 p27 in FLT3-driven acute myeloid leukemia: many roads lead to ruin
2017 Generation Of Immortal Murine Hematopoietic Stem/ Progenitor Cell Lines From Transgenic Mice.
2017 Lack of Stat1 Predisposes to a Diffuse Large B-Cell Lymphoma-Like Disease.
2017 Maintenance Of Leukaemogenic Potential Of Bcr/Abl Plus Cells Requires Pak2 But Not Pak1 .
2017 Targeted Combination Therapy With Cdk4/6 Inhibitor Palbociclib In AML.
2017 The Novel Switch Control Inhibitor Dcc-2618 Counteracts Growth and Survival Of Various Neoplastic Cells, Including Mast Cells, Eosinophils, and Monocytes, In Patients With Systemic Mastocytosis.
2016 Activated Stat5 Drives Peripheral T Cell Lymphomas.
2016 High expression of AF1Q is an adverse prognostic factor and a prediction marker of extramedullary disease in multiple myeloma.
2016 Identification of a novel STAT5 inhibitor to interfere with the oncogenic activities of STAT5 in AML.
2016 Targeting of BRD4 as a novel therapeutic concept in JAK2 v617F+MPN.
2015 Activated STAT5 as novel stem cell target in JAK2 V617F positive myeloproliferative neoplasms (MPN).
2015 Identification and characterization of putative neoplastic stem cells in patients with mast cell leukemia.
2015 The B-Cell Receptor Pathway is Highly Actived in Canine DLBCL Cell Line CLBL-1.
2015 The Tyk2 Pathway as a Novel Therapeutic Intervention Site in Aggressive T-Cell Lymphoma.
2014 Co-operating STAT5 and AKT signaling pathways in chronic myeloid leukemia and mastocytosis: possible new targets of therapy.
2014 Lactotransferrin-Cre reporter mice trace neutrophils, monocytes/macrophages and distinct subtypes of dendritic cells.
2014 Acceleration Of Bcr-Abl Plus Leukemia Induced By Deletion Of JAK2.
2014 Pro-Atherogenic And Anti-Angiogenic Effects Of Nilotinib On Endothelial Cells: A Potential Mechanism To Explain Vasculopathies In Cml Patients Treated With Nilotinib.
2014 The Epigenetic Reader Brd4 Serves As A Novel Marker And Target In Aggressive Systemic Mastocytosis And Mast Cell Leukemia.
2014 The KI-1 Antigen (CD30) Is A Novel Marker And Potential Therapeutic Target In Advanced Systemic Mastocytosis.
2014 The Multikinase Inhibitor R763/AS703569 Blocks Stat5 Activity And Induces Apoptosis In Neoplastic Human Mast Cells.
2013 Synergistic growth-inhibitory effects of ponatinib and midostaurin (PKC412) on neoplastic mast cells carrying KIT D816V.
2013 Evaluation Of Growth-Inhibitory And Histamine Release-Targeting Effects Of Pkc412 And Its Metabolites On Neoplastic Mast Cells By Chemical Proteomics Profiling And Target Validation.
2013 Identification Of Campath-1 (CD52) As A Drug Target In Neoplastic Stem Cells In 5Q-Patients With MDS Or AML.
2013 Neoplastic Stem Cells Of Ph Plus Chronic Myeloid Leukemia (Cml) Express The Alpha-Chain Of The Il-2 Receptor (Cd25).
2012 A new Prognostic Score for Aggressive B-Cell Lymphoma with C-Myc Translocation Integrating Clinical and Genetic Features.
2012 AP-1 Impacts On Angiogenesis in BCR/ABL Driven Disease.
2012 CDK6 in HSC Homeostasis.
2012 STAT1-Deficient Mice Develop a Myeloproliferative Syndrome Resembling Human CML.
2011 Polo-like kinase-1 as a novel target in neoplastic mast cells: demonstration of growth-inhibitory effects of small interfering RNA and the Polo-like kinase-1 targeting drug BI 2536.
2010 Identification Of Polo-Like Kinase-1 (Plk-1) As A Novel Drug Target In Neoplastic Mast Cells In Systemic Mastocytosis.
2010 Mutations in KIT Predict Resistance to Several TKI (Sorafenib, Sunitinib, and Masatinib) in Neoplastic Human and Canine Mast Cell Lines.
2010 The Aurora-Kinase Inhibitor As703569 Exerts Growth-Inhibitory And Apoptosis-Inducing Effects In Primary Cml Cells And Cell Lines Expressing Various Imatinib-Resistant Bcr/Abl Mutants.
2009 The Bh3 Mimetic Gx015-070 (Obatoclax) Induces Apoptosis And Growth Inhibition In Neoplastic Mast Cells.
2007 Aggressive systemic mastocytosis with sarcoma-like growth in the skeleton, leukemic progression, and partial loss of mast cell differentiation antigens.
2007 Identification of heme oxygenase-1 (HO-1=Hsp32) as a novel therapeutic target in canine mastocytoma cells.
-
2025
Cyclin C promotes development and progression of B-cell acute lymphoblastic leukemia by counteracting p53-mediated stress responses
2023 Oncogenic TYK2P760L kinase is effectively targeted by combinatorial TYK2, mTOR and CDK4/6 kinase blockade.
2021 Inducible deletion of CDK4 and CDK6-deciphering CDK4/6 inhibitor effects in the hematopoietic system
2021 Whole exome sequencing reveals NOTCH1 mutations in anaplastic large cell lymphoma and points to Notch both as a key pathway and a potential therapeutic target
2020 High activation of STAT5A drives peripheral T-cell lymphoma and leukemia
2019 The stromal microenvironment provides an escape route from FLT3 inhibitors through the GAS6-AXL-STAT5 axis.
2018 Normal and pathological erythropoiesis in adults: from gene regulation to targeted treatment concepts
2018 The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis
2017 Cdk6 contributes to cytoskeletal stability in erythroid cells
2017 Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemia.
2017 p27 in FLT3-driven acute myeloid leukemia: many roads lead to ruin
2017 Generation Of Immortal Murine Hematopoietic Stem/ Progenitor Cell Lines From Transgenic Mice.
2017 Lack of Stat1 Predisposes to a Diffuse Large B-Cell Lymphoma-Like Disease.
2017 Maintenance Of Leukaemogenic Potential Of Bcr/Abl Plus Cells Requires Pak2 But Not Pak1 .
2017 Targeted Combination Therapy With Cdk4/6 Inhibitor Palbociclib In AML.
2017 The Novel Switch Control Inhibitor Dcc-2618 Counteracts Growth and Survival Of Various Neoplastic Cells, Including Mast Cells, Eosinophils, and Monocytes, In Patients With Systemic Mastocytosis.
2016 Activated Stat5 Drives Peripheral T Cell Lymphomas.
2016 High expression of AF1Q is an adverse prognostic factor and a prediction marker of extramedullary disease in multiple myeloma.
2016 Identification of a novel STAT5 inhibitor to interfere with the oncogenic activities of STAT5 in AML.
2016 Targeting of BRD4 as a novel therapeutic concept in JAK2 v617F+MPN.
2015 Activated STAT5 as novel stem cell target in JAK2 V617F positive myeloproliferative neoplasms (MPN).
2015 Identification and characterization of putative neoplastic stem cells in patients with mast cell leukemia.
2015 The B-Cell Receptor Pathway is Highly Actived in Canine DLBCL Cell Line CLBL-1.
2015 The Tyk2 Pathway as a Novel Therapeutic Intervention Site in Aggressive T-Cell Lymphoma.
2014 Co-operating STAT5 and AKT signaling pathways in chronic myeloid leukemia and mastocytosis: possible new targets of therapy.
2014 Lactotransferrin-Cre reporter mice trace neutrophils, monocytes/macrophages and distinct subtypes of dendritic cells.
2014 Acceleration Of Bcr-Abl Plus Leukemia Induced By Deletion Of JAK2.
2014 Pro-Atherogenic And Anti-Angiogenic Effects Of Nilotinib On Endothelial Cells: A Potential Mechanism To Explain Vasculopathies In Cml Patients Treated With Nilotinib.
2014 The Epigenetic Reader Brd4 Serves As A Novel Marker And Target In Aggressive Systemic Mastocytosis And Mast Cell Leukemia.
2014 The KI-1 Antigen (CD30) Is A Novel Marker And Potential Therapeutic Target In Advanced Systemic Mastocytosis.
2014 The Multikinase Inhibitor R763/AS703569 Blocks Stat5 Activity And Induces Apoptosis In Neoplastic Human Mast Cells.
2013 Synergistic growth-inhibitory effects of ponatinib and midostaurin (PKC412) on neoplastic mast cells carrying KIT D816V.
2013 Evaluation Of Growth-Inhibitory And Histamine Release-Targeting Effects Of Pkc412 And Its Metabolites On Neoplastic Mast Cells By Chemical Proteomics Profiling And Target Validation.
2013 Identification Of Campath-1 (CD52) As A Drug Target In Neoplastic Stem Cells In 5Q-Patients With MDS Or AML.
2013 Neoplastic Stem Cells Of Ph Plus Chronic Myeloid Leukemia (Cml) Express The Alpha-Chain Of The Il-2 Receptor (Cd25).
2012 A new Prognostic Score for Aggressive B-Cell Lymphoma with C-Myc Translocation Integrating Clinical and Genetic Features.
2012 AP-1 Impacts On Angiogenesis in BCR/ABL Driven Disease.
2012 CDK6 in HSC Homeostasis.
2012 STAT1-Deficient Mice Develop a Myeloproliferative Syndrome Resembling Human CML.
2011 Polo-like kinase-1 as a novel target in neoplastic mast cells: demonstration of growth-inhibitory effects of small interfering RNA and the Polo-like kinase-1 targeting drug BI 2536.
2010 Identification Of Polo-Like Kinase-1 (Plk-1) As A Novel Drug Target In Neoplastic Mast Cells In Systemic Mastocytosis.
2010 Mutations in KIT Predict Resistance to Several TKI (Sorafenib, Sunitinib, and Masatinib) in Neoplastic Human and Canine Mast Cell Lines.
2010 The Aurora-Kinase Inhibitor As703569 Exerts Growth-Inhibitory And Apoptosis-Inducing Effects In Primary Cml Cells And Cell Lines Expressing Various Imatinib-Resistant Bcr/Abl Mutants.
2009 The Bh3 Mimetic Gx015-070 (Obatoclax) Induces Apoptosis And Growth Inhibition In Neoplastic Mast Cells.
2007 Aggressive systemic mastocytosis with sarcoma-like growth in the skeleton, leukemic progression, and partial loss of mast cell differentiation antigens.
2007 Identification of heme oxygenase-1 (HO-1=Hsp32) as a novel therapeutic target in canine mastocytoma cells.